Evaluating the Safety and Efficacy of Lactobacillus Plantarum in Treating Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Conditions
- PsoriasisLactobacillus Plantarum
- Interventions
- Biological: inactivated Lactobacillus plantarum
- Registration Number
- NCT07194200
- Lead Sponsor
- Shenzhen People's Hospital
- Brief Summary
A growing body of evidence indicates that the pathogenesis of psoriasis may be closely linked to skin microbiome dysbiosis. Compared with healthy individuals, the composition and function of the skin microbiota in psoriasis patients exhibit significant alterations5,6. This microbial imbalance is thought to contribute to the initiation and progression of the disease through mechanisms such as triggering abnormal immune responses, exacerbating inflammatory processes, and impairing the skin barrier.
In-depth exploration of the interplay between psoriasis and the microbiome not only offers new perspectives for elucidating the disease's pathogenesis but also lays the groundwork for developing innovative microbiota-targeted diagnostic and therapeutic strategies. Thus, identifying novel therapeutic approaches that bridge psoriasis treatment and microbial regulation holds substantial clinical and social value.
While existing treatments for psoriasis have made some progress, research specifically focusing on the microbiota-psoriasis relationship remains relatively limited. Investigating the intrinsic connections between microecological balance and psoriasis management, and developing practical improvement strategies, is therefore of crucial practical significance for enhancing skin health and improving quality of life. This study aims to address this research gap and provide a new therapeutic option for individuals with psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 184
- Reference to Psoriasis Area and Severity Index (PASI) score < 10 Patients have been informed of the study details, voluntarily participate, and have signed the informed consent form; Aged 18-60 years with good general health status; No use of any medications within 6 months; No various inflammatory or immune skin diseases, no local infections, and no neuromuscular diseases.
- Patients with other types of psoriasis or severe psoriasis; Those in the active phase of skin diseases or with other serious diseases; Other situations deemed unsuitable for enrollment by the researchers, such as subjects who are untrustworthy, unable to accept or understand the study assessments.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description group A Lactobacillus plantarum Intervention measures for the experimental group: Apply 5ml of Lactobacillus plantarum solution extracted from the skin surface of healthy individuals to the psoriatic lesions daily, for a duration of 2 months. group B inactivated Lactobacillus plantarum Intervention measures for the control group: Apply 5ml of inactivated Lactobacillus plantarum solution to the psoriatic lesions daily, for a duration of 2 months.
- Primary Outcome Measures
Name Time Method TEWL The follow-up periods are set at 1, 2, 4, and 8 weeks after the initial treatment. Take general appearance photographs and dermoscopic images, and simultaneously use a transdermal water loss instrument to measure the degree of transepidermal water loss.
General appearance photography The follow-up periods are set at 1, 2, 4, and 8 weeks after the initial treatment. After shooting, three professional doctors will independently assess the improvement of psoriatic lesions in patients.
Dermoscopic photography The follow-up periods are set at 1, 2, 4, and 8 weeks after the initial treatment. After shooting, three professional doctors will independently assess the improvement of psoriatic lesions in patients.
Completion of self-assessment questionnaires The follow-up periods are set at 1, 2, 4, and 8 weeks after the initial treatment. Record the improvement of patients' self-perceived suboptimal skin conditions after treatment compared with the baseline.
Adverse reactions The follow-up periods are set at 1, 2, 4, and 8 weeks after the initial treatment. Subjects will record predefined expected post-treatment events at the treated sites.
- Secondary Outcome Measures
Name Time Method